Cancer treatment developer Rakuten Medical has received $100m in series C1 capital from affiliate Rakuten, which now holds a 22.6% stake.

E-commerce firm Rakuten has provided $100m in series C1 financing for Rakuten Medical, the US-based cancer-focused biotechnology developer formerly known as Aspyrian Therapeutics. Rakuten now owns 22.6% of the company, which will become an equity-method affiliate in Q3 2019. The series C1 round follows a $284m series C round closed in December 2018 that featured…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.